Please assess the completion status of the following clinical trial:

Trial Title: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy~* Confirmed diagnosis of HR+/HER2- breast cancer~* Any menopausal status~* Progressed within 12 months from prior adjuvant or progressed within 1 month from prior advanced/metastatic endocrine breast cancer therapy~* On an LHRH agonist for at least 28 days, if pre-/peri-menopausal, and willing to switch to goserelin (Zoladex ®) at time of randomization.~* Measurable disease defined by RECIST version 1.1, or bone-only disease~* Eastern Cooperative Oncology Group (ECOG) PS 0-1~* Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures~* Patient must agree to provide tumor tissue from metastatic tissue at baseline~Exclusion Criteria:~* Prior treatment with any CDK inhibitor, fulvestrant, everolimus, or agent that inhibits the PI3K-mTOR pathway~* Patients with extensive advanced/metastatic, symptomatic visceral disease, or known uncontrolled or symptomatic CNS metastases~* Major surgery or any anti-cancer therapy within 2 weeks of randomization~* Prior stem cell or bone marrow transplantation~* Use of potent CYP3A4 inhibitors or inducers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
- Arm B (Type: ACTIVE_COMPARATOR): Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).